Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APALUTAMIDE vs ANDROID 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Apalutamide is a nonsteroidal antiandrogen that inhibits androgen receptor (AR) nuclear translocation, DNA binding, and transcription of AR target genes. It also decreases AR-mediated tumor cell proliferation and increases apoptosis.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Metastatic castration-sensitive prostate cancer (m CSPC),Non-metastatic castration-resistant prostate cancer (nm CRPC)
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
240 mg orally once daily with or without food.
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Terminal elimination half-life is approximately 3 days (72 hours) for apalutamide and 3–5 days for the active metabolite N-desmethyl-apalutamide. The long half-life supports once-daily dosing and requires approximately 2–3 weeks to reach steady state.
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Primarily metabolized by CYP2C8 and CYP3A4 to active metabolite N-desmethylapalutamide. Also involves glucuronidation by UGTs.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Apalutamide and its active metabolite N-desmethyl-apalutamide are eliminated primarily via hepatic metabolism and subsequent fecal excretion. Approximately 65% of the dose is recovered in feces (as unchanged drug and metabolites) and 24% in urine (primarily as metabolites). Renal excretion of unchanged drug is negligible.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Apalutamide is highly protein bound (>96%), primarily to albumin and alpha-1-acid glycoprotein. No significant displacement interactions are expected with other highly bound drugs.
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Apparent volume of distribution (Vd/F) is approximately 200 L (2.7 L/kg for a 70 kg adult), indicating extensive distribution into tissues including the prostate and other androgen-responsive organs.
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
Oral bioavailability is not precisely determined due to lack of an intravenous formulation, but absorption is at least 90% based on mass balance studies. Food does not significantly affect absorption, so it can be taken with or without food.
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). For severe renal impairment (e GFR 15-29 m L/min), use with caution; no specific dose recommendation. Not studied in end-stage renal disease (e GFR <15 m L/min) or on hemodialysis.
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
Mild hepatic impairment (Child-Pugh A): No dose adjustment. Moderate hepatic impairment (Child-Pugh B): Reduce dose to 120 mg once daily. Severe hepatic impairment (Child-Pugh C): Not recommended due to lack of data.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Safety and efficacy not established; no approved pediatric dosing.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
No specific dose adjustment required; consider comorbidities and potential for increased adverse effects based on renal and hepatic function.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
None.
None
Seizures: Discontinue permanently if seizure occurs during treatment.,Fractures and Falls: Increased risk of bone fractures and falls; assess bone density and manage accordingly.,Cardiovascular Events: Increased risk of hypertension, cardiac ischemia, and heart failure; monitor cardiovascular status.,Hypothyroidism: Monitor thyroid function before and during treatment; replacement therapy may be needed.,Embryo-Fetal Toxicity: Can cause fetal harm; advise males with female partners of reproductive potential to use effective contraception.
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Pregnancy (can cause fetal harm),Women of reproductive potential (unless using effective contraception)
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction. No other specific dietary restrictions; can be taken with or without food.
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
Apalutamide is contraindicated in pregnancy. Based on its mechanism of androgen receptor inhibition, it may cause fetal harm, including feminization of male fetuses and developmental abnormalities. Adequate animal reproduction studies have not been conducted; however, in rats, fetal malformations were observed at exposures below human clinical exposures. Effective contraception is required for females of reproductive potential during treatment and for 3 months after the last dose.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
It is unknown whether apalutamide or its metabolites are excreted in human milk. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 3 months after the last dose. M/P ratio is not available.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
No dosing adjustments have been established for pregnancy. Apalutamide is not indicated for use in pregnant women. Physiological changes in pregnancy may alter pharmacokinetics, but no data are available to guide dose modifications.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
Apalutamide is an androgen receptor inhibitor used for non-metastatic castration-resistant prostate cancer (nm CRPC). It is a strong CYP3A4 inducer and moderate CYP2C8 inhibitor, requiring careful management of drug interactions. Monitor thyroid function and blood pressure. Concomitant use with warfarin or other anticoagulants may necessitate increased monitoring due to reduced efficacy. Apalutamide can cause seizures; avoid in patients with history of seizure disorders. Baseline and periodic serum lipid profiles and glucose levels are recommended. Dose reduction in severe hepatic impairment (Child-Pugh C) is suggested.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
Take apalutamide with or without food, at the same time each day.,Do not crush, chew, or split tablets; swallow whole.,Avoid grapefruit and grapefruit juice during treatment.,Report signs of seizure, high blood pressure, or thyroid abnormalities to healthcare provider immediately.,Use effective contraception during treatment and for 3 months after last dose; apalutamide may reduce hormonal contraceptive effectiveness.,Inform all healthcare providers of apalutamide use due to potential drug interactions.,May cause fatigue, dizziness, or hot flashes; avoid driving if affected.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APALUTAMIDE vs ANDROID 10, answered by our medical review team.
APALUTAMIDE is a Androgen Receptor Inhibitor that works by Apalutamide is a nonsteroidal antiandrogen that inhibits androgen receptor (AR) nuclear translocation, DNA binding, and transcription of AR target genes. It also decreases AR-mediated tumor cell proliferation and increases apoptosis.. ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APALUTAMIDE and ANDROID 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APALUTAMIDE is: 240 mg orally once daily with or without food.. The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APALUTAMIDE and ANDROID 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APALUTAMIDE is classified as Category C. Apalutamide is contraindicated in pregnancy. Based on its mechanism of androgen receptor inhibition, it may cause fetal harm, including feminization of male fetuses and development. ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.